Recent News
Read ArticleDr. Jack Cush reviews the news, journal articles and missed quiz questions.
“Common sense in matters medical is rare, and is usually in inverse ratio to the degree of education.”
– Sir William Osler
Dr. John Cush @RheumNow ( View Tweet)
Which of the following is NOT a complication of Gout?
Dr. John Cush @RheumNow ( View Tweet)
FDA has approved that guselkumab (Tremfya) for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA) https://t.co/Xev5hnheRz https://t.co/AyP2wE8vLu
Dr. John Cush @RheumNow ( View Tweet)
Review of Ruxolitinib in 7 pts w/ refractory systemic JIA complicated by macrophage activation (MAS) (ages 1.6-11 yrs; 3M: 4F). 5 achieved complete remission; 2 partial remission. 2 relapsed w/ GC tapering (remission after adding canakinumab). No deaths https://t.co/j4Cm3UYB9c https://t.co/pKoDwpSKII
Dr. John Cush @RheumNow ( View Tweet)
RepurpSS-II: Hydroxychloroquine plus Leflunomide in Sjögren's
A small pilot, phase 2b trial has shown that the combination of leflunomide and hydroxychloroquine (LEF+HCQ) was effective and safe in treating patients with active Sjögren's disease.
https://t.co/eeyhso0WJ6 https://t.co/ZGWOOtf92E
Dr. John Cush @RheumNow ( View Tweet)
True or False: After successfully treating herpes zoster, it is considered safe to restart anti-TNF therapy without a significant risk of recurrence. See if you got it right in this week's RheumIQ quiz at https://t.co/DX0qT1iNF2 https://t.co/pGggdVPhmh
Dr. John Cush @RheumNow ( View Tweet)
Cross-sectional study of 339 IBD pts (64% women, median 42yrs (32–53) found osteopenia by BMD in 34%, OP in 12%. Predictors not identified by multivariable analysis. Rheum eval led to OP Rx in 7% & vitamin D in 45% https://t.co/a9RSo9PxHS https://t.co/nIOR9AUjQs
Dr. John Cush @RheumNow ( View Tweet)
Retrospective Intl SSc study of MD & PT telangiectasia counts (TC) (0, 1–6, 7–15 or > 15) of face, forearms & hands. High TC correlated w/ PAH (AUC 0.824–0.875) & digital ulcers. Moderate agreement betw MD & Pt for face & forearms TC (kappa 0.648 & 0.605, p< 0.001) https://t.co/k7tVeJFeCi
Dr. John Cush @RheumNow ( View Tweet)
In the cross-sectional study of US SLE patients, what was the most common drug class driving polypharmacy beyond SLE medications? Test your knowledge in this week's RheumIQ quiz at https://t.co/DX0qT1iNF2 https://t.co/ox4rGp04WH
Dr. John Cush @RheumNow ( View Tweet)
EGPA https://t.co/zlquehIZQ6
Rheumatology update @aabdogafar ( View Tweet)
FDA has approved that guselkumab (Tremfya) for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA) https://t.co/KwcECQpSz1 https://t.co/pSoK930FAX
Dr. John Cush @RheumNow ( View Tweet)
LRA Awards for Immune Resetting Therapies in Lupus
LRA, the world’s largest private funder of lupus research, in collaboration with Genentech, a member of the Roche Group, announced the inaugural recipients of the Lupus Research Alliance-Genentech Award on Immune Resetting https://t.co/eDAq17lhM0
Dr. John Cush @RheumNow ( View Tweet)
Veterans Administration study of 301 #RA pts Rx w/ immune checkpoint inhibitor (ICI) for cancer shows all cause mortality in ICI Rx Cancer pts was no worse when RA pts took ICIs (1.09; 0.94–1.25). Cause of death similar; Infx were rare (<1.0%) https://t.co/3ZYujU5nyE https://t.co/MCDcdWHcVx
Dr. John Cush @RheumNow ( View Tweet)
Review of Ruxolitinib in 7 pts w/ refractory systemic JIA complicated by macrophage activation (MAS) (ages 1.6-11 yrs; 3M: 4F). 5 achieved complete remission; 2 partial remission. 2 relapsed w/ GC tapering (remission after adding canakinumab). No deaths https://t.co/j4Cm3UYB9c https://t.co/YIupsBank5
Dr. John Cush @RheumNow ( View Tweet)
Adverse drug events (ADEs) studied in autoimmune rheum Dz (ARDs). In 10,578 ARD pts 30% had 1+ ADE, highest in SSc (36%). Polypharmacy (57.3% minor, 39.4% major) contrib to increasing ADEs. ADEs were more from Sx Rx (antacids, Tylenol, psychotropics) than DMARDs. https://t.co/BOAfU1DyIN
Dr. John Cush @RheumNow ( View Tweet)
Increased Polypharmacy in SLE Patients
A cross-sectional study of US adults with systemic lupus erythematosus (SLE) shows significantly increased prevalence of polypharmacy, related to age, disease outcomes and often, non-SLE common medications.
Korean claims data on FX in RA (2010-2017; n = 43,677). RA had more FX (aHR 1.68), regardless of b/tsDMARD use. Seropositive had more Fx (aHR 1.19), Vertebral Fx (aHR 1.4) & hip Fx (aHR 1.55) VS seronegative RA https://t.co/5Fm3o841H7 https://t.co/V0L87JYtba
Dr. John Cush @RheumNow ( View Tweet)
Hopkins study of HCQ in discoid lupus (DLE) - 5 yr outcomes of 106 adult DLE; those on HCQ had less hyperlipidemia (HL), PAD, angina, & CAD. Parallel TriNetX study showed HCQ assoc w/ signif less HTN, HL, DM, CAD, & CVA. https://t.co/yX7FkGCnvR https://t.co/oddq68FYeE
Links:
Dr. John Cush @RheumNow ( View Tweet)
WSJ: Nurse Practitioner Is Now the Hottest Job in Healthcare
The Wall St. Journal has published a perspective on nurse practitioners (NP) and their very promising careers.
https://t.co/YUasxB43ZO https://t.co/tkvKh0JEui
Dr. John Cush @RheumNow ( View Tweet)
From the Blog
Podcasts
Count Your Telangiectasias (5.29.2026)-
Quiz Talk (5.22.2026)
-
Infectious Rheumatology (5.15.2026)
-
Influential Rheumatoid Factors(5/8/2026)
Therapeutic Updates
Expert insights on the 2024 ACR Guideline recommendations for lupus nephritis
Sponsored by Aurinia
Two experts in lupus care offer a balanced perspective on applying the updated ACR Guideline recommendations and the clinical nuances of managing lupus nephritis.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
